Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …

The Omicron, or Pango lineage B. 1.1. 529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …

The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron
subvariants, including BQ. 1, BQ. 1.1, BA. 4.6, BF. 7, and BA. 2.75. 2. Here, we examine the …

Neutralization of Omicron BA. 1 and BA. 2 Variants Although two doses of BNT162b2
vaccine produce immunity that wanes over time, the administration of a booster dose …